Dear Editor,

Arsenic trioxide (As~2~O~3~) is a standard medication for relapsed acute promyelocytic leukemia (APL). However, high blood arsenic levels lead to potentially fatal arrhythmias. As~2~O~3~ is renal-excreted and considered contraindicated in renal failure.

A 42-year-old man was referred for treatment of APL in first relapse, presenting with pancytopenia, impaired renal function, and septicemia. He was treated with all-trans retinoic acid (ATRA, 45 mg/m^2^/day) and oral As~2~O~3~ (10 mg/day) \[[@CR1]\]. Progressive renal function derangement developed, necessitating reduction of oral As~2~O~3~ to 5 mg/day. On the third day, the leukocyte count increased to 8.9 × 10^9^/L, associated with bilateral pulmonary infiltrates. Features were consistent with the APL differentiation syndrome, which with the underlying septicemia led to anuric acute renal failure. ATRA was stopped. Idarubicin (6 mg/m^2^/day × 5), dexamethasone (12 mg/day × 7), and alternate daily hemodialysis were administered. Oral As~2~O~3~ at 5 mg was given after each hemodialysis and was stopped after 9 days. At 4 weeks, marrow examination confirmed complete remission. He remained anuric, and hemodialysis was continued. Oral As~2~O~3~ was re-commenced at 2 mg after each hemodialysis. Two months later, continuous ambulatory peritoneal dialysis (CAPD) was started. A maintenance regimen for APL, comprising oral As~2~O~3~ (5 mg/day) and ATRA (20 mg twice daily) \[[@CR2], [@CR3]\], given 2 weeks every 2 months, was administered. At 6-month follow-up, he remained in remission and was negative for the *PML-RARA* fusion gene characteristic of APL. No cardiac arrhythmias were observed at any time.

Serum elemental arsenic levels were assayed by inductively coupled plasma mass spectrometry \[[@CR3], [@CR4]\], on blood samples sent for creatinine measurement. At 4 days, there was a sudden increase of arsenic levels, as the cellular and third-space compartments became saturated and anuria prevented arsenic excretion (Fig. [1a](#Fig1){ref-type="fig"}). The arsenic level peaked at 4,240 nmol/L, outside the therapeutic range of 500--2,000 nmol/L typical of oral As~2~O~3~. The commencement of hemodialysis and cessation of oral As~2~O~3~ resulted in a fall of arsenic levels parallel to those of creatinine. After oral As~2~O~3~ was re-commenced, arsenic levels gradually increased to the therapeutic range (Fig. [1b](#Fig1){ref-type="fig"}). As arsenic clearance in oral As~2~O~3~ therapy during CAPD had been documented previously \[[@CR3]\], arsenic assays were not performed after peritoneal dialysis was started.Fig. 1**a** Blood arsenic levels during the first 3 weeks of hemodialysis. A rapid surge of arsenic levels occurred on day 5, in parallel with a rise in creatinine and further renal function deterioration. Oral arsenic trioxide was stopped on day 9, resulting in a gradual fall of arsenic levels after hemodialysis was commenced. Days (sample number): 3 (1--4), 4 (5--7), 5 (8), 6 (9), 7 (10--13), 8 (14--16), 9 (17--19), 10 (20--21), 11 (22), 12 (23), 13 (24), 14 (24--26), 15 (28--30), 16 (31--32), 17 (33--34), 18 (35--36), 19 (37--38), 20 (39), 21 (40), 22 (41), 23 (42), and 24 (43). **b** Blood arsenic levels during the second month of hemodialysis. With the re-commencement of oral arsenic trioxide on day 42, there was a gradual increase of arsenic levels back to the therapeutic range. Arsenic levels also varied in parallel with creatinine levels during hemodialysis and had remained within the therapeutic range

As~2~O~3~ is a key medication for patients with relapsed APL. Intravenous (i.v.) As~2~O~3~, used in most reports, may lead to lethal arrhythmias due to QT prolongation, which is directly proportional to blood arsenic levels \[[@CR5]\]. Because i.v. As~2~O~3~ leads to a rapid surge of blood arsenic levels, arrhythmia related to QT prolongation is an important adverse effect. Oral As~2~O~3~ is slowly absorbed and results in lower blood arsenic levels. Its bioavailability, estimated by area-under-the-curve pharmacokinetically, is comparable to that of i.v. As~2~O~3~ \[[@CR6]\]. Hence, oral As~2~O~3~ has the same efficacy, but little risk of arrhythmia \[[@CR5]\]. In one previous report, blood arsenic levels after i.v. As~2~O~3~ were measured in an APL patient on hemodialysis \[[@CR7]\]. The peak level was 6,450 nmol/L, a toxic level that led to termination of i.v. As~2~O~3~ therapy. It was concluded that i.v. As~2~O~3~ was contraindicated in renal failure \[[@CR7]\]. In our case, the sudden increase in blood arsenic levels was related to an unanticipated acute renal failure. Timely cessation of oral As~2~O~3~ and institution of hemodialysis prevented further increases in arsenic levels. Subsequently, with careful dose adjustment and meticulous monitoring, oral As~2~O~3~ was safely administered during hemodialysis. The blood arsenic levels were also kept within the therapeutic range. We have also previously demonstrated the safety of oral As~2~O~3~ during CAPD. Therefore, patients on renal replacement therapy are still eligible for oral As~2~O~3~ treatment.
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